Home » Manufacturing Issues Are Cause Of Impax NDA Rejection
Manufacturing Issues Are Cause Of Impax NDA Rejection
The FDA’s rejection of Impax Pharmaceuticals’ extended-release capsule Rytary for the treatment of idiopathic Parkinson’s disease points to continuing problems at a California manufacturing site.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May